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Abstract
Background: Certain early-phase clinical trials have suggested that bone marrow-derived stem cell transplantation
might improve left ventricular function in patients with non-ischaemic dilated cardiomyopathy (NIDCM), whereas
others trials have revealed no benefit from this approach. We sought to evaluate the therapeutic effects of bone
marrow-derived stem cell therapy on NIDCM.
Methods: We searched the PubMed, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL)
databases (through February 2016) for randomised controlled clinical trials that reported on bone marrow-derived
stem cell transplantation for patients with NIDCM with a follow-up period ≥12 months. The co-primary endpoints
were changes in mortality rate and left ventricular ejection fraction (LVEF); the secondary endpoints were changes
in the 6-minute-walk test (6MWT) and left ventricular chamber size. Seven trials involving bone marrow-derived
stem cell therapy that included 482 patients satisfied the inclusion and exclusion criteria.
Results: Subjects who received bone marrow-derived stem cell therapy exhibited a significant reduction in mortality rate
(19.7% in the cell group vs. 27.1% in the control group; 95% confidence interval (CI) –0.16 to –0.00, I2 = 52%, p = 0.04).
Bone marrow-derived stem cell therapy tended to produce LVEF improvement within 6 months (1.83% increase; 95% CI
–0.27 to 3.94, I2 = 74%, p = 0.09) and significantly improved LVEF after mid-term (6–12 months) follow-up (3.53% increase;
95% CI 0.76 to 6.29, I2 = 88%, p = 0.01). However, this therapy produced no significant benefit in the 6MWT (p= 0.18).
Finally, the transplantation of increased numbers of stem cells resulted in no observable additional benefit with respect to
LVEF.
Conclusions: Bone marrow-derived stem cell therapy might have improved prognoses and appeared to provide
moderate benefits in cardiac systolic function at mid-term follow-up. However, this therapy produced no observed
improvement in exercise tolerance.
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Background
Non-ischaemic dilated cardiomyopathy (NIDCM) is a
major cause of heart failure (HF) and the primary indi-
cation for heart transplantation [1, 2]. The prevalence of
this disease tends to increase with population age, and
survival has improved due to advances in pharmaco-
logical treatment and implantable devices [3]. However,
current therapeutic approaches are palliative in that they
cannot directly address the underlying problem of the
loss of cardiac tissue [4].
Although multiple studies have recently investigated the
potential role of stem cell therapy for NIDCM [5–11], in
the burgeoning field of cell therapy for HF, NIDCM has
been studied much less frequently than ischaemic cardio-
myopathy (ICM). Two small trials found that the adminis-
tration of bone marrow mononuclear cells (BMMNCs) via
an intracoronary route produced a small but significant
increase in left ventricular ejection fraction (LVEF) [7, 12].
Recently, a study demonstrated that an intracoronary
injection of CD34+ cells was associated with mid-term
improvement in ventricular function, exercise tolerance,
and long-term survival in a randomised trial of patients
with NIDCM [5]. However, two other recent publications
[8, 9] reached contradictory results regarding the impact
of stem cell therapy on NIDCM patients.
The questions of whether intracoronary cell therapy
improves left ventricular morphology and function and
how persistent this effect may be remain unresolved.
Our goal was to systematically summarize randomised
controlled trials (RCTs) by conducting a meta-analysis of
the impact of bone marrow-derived stem cell therapy on
NIDCM patients that can serve as a reference for further
clinical trials and management.
Methods
Review question and study protocol
This review assessed RCTs that examined the effects of adult
bone marrow-derived stem cell transplantation on NIDCM.
Eligibility criteria and search strategy
We searched the PubMed, Embase, Science Citation
Index, and the Cochrane Central Register of Controlled
Trials (CENTRAL) databases for papers published
through February 2016. Additionally, we searched the
American College of Cardiology, American Heart
Association, European Society of Cardiology, and
internet-based sources of information regarding clinical
trials in cardiology for RCTs from 2000 to 2016, without
language restrictions. The following keywords were used:
“non-ischemic cardiomyopathy”, “dilated cardiomyop-
athy”, “stem cell”, “bone marrow cell”, “mesenchymal stem
cell”, “haematopoietic stem cells”, and “progenitor stem
cell”. The initially selected citations were screened at the
title/abstract level. Potentially relevant publications were
retrieved, and the complete manuscripts were assessed for
compliance with these inclusion criteria: 1) a prospective
comparison of stem cell therapy versus control for
NIDCM patients; 2) an intention-to-treat analysis; 3) re-
ported data that include changes in LVEF before and after
intervention; and 4) a follow-up period >12 months. The
exclusion criteria were: 1) irretrievable or unclear data; 2)
lack of a control group or a control arm that also received
stem cells; 3) duplicated reports; and 4) on-going or un-
published studies.
Data extraction
Study features were extracted, including study design,
outcome definitions, imaging modalities, patients’ base-
line characteristics, and procedural data. Changes in the
mortality rate, LVEF, left ventricular end-systolic volume
(LVESV), left ventricular end-diastolic dimension
(LVEDD), and walk test from baseline to follow-up were
collected. If remodelling volume was reported based on
multiple imaging techniques, the volume with the
smaller standard error was chosen for analysis [13]. The
mortality rate, which was evaluated at the longest avail-
able follow-up time, was also collected. Two authors in-
dependently performed the literature search and data
extraction. In cases with missing or unclear data for the
primary or secondary endpoints, the primary authors
were contacted on at least two different occasions sepa-
rated by an interval of at least 3 weeks.
Outcomes
The co-primary endpoints were changes in mortality rate
and LVEF from baseline to follow-up. The secondary effi-
cacy endpoints were changes in the 6-minute-walk test
(6MWT) and left ventricular chamber size. Data were
separated into short-term (<6 months) and mid-term
(6–12 months) subgroups.
Quality assessment
Quality assessment was performed by utilizing the
Cochrane Collaboration’s tool for assessing risk of bias
criteria in accordance with the PRISMA statement [14].
Statistical analyses
Statistical analyses were performed using RevMan 5.3.
For continuous parameters, weighted mean differences
(WMDs) were calculated using mean values, their corre-
sponding standard deviations, and treatment arm sizes.
Moreover, data were analysed using 95% confidence in-
tervals (CIs). The percentage of variability across studies
attributable to heterogeneity beyond chance was esti-
mated using I2. I2 > 75% indicated high heterogeneity. A
fixed-effect model was adopted when heterogeneity
existed (I2 > 75%); otherwise, a random-effect model was
used. A forest plot was used to display the WMD and
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95% CI for each study. A two-sided p value <0.05 was
regarded as significant.
Sensitivity analyses and publication bias
Given the small number of studies in our pooled ana-
lysis, we tested the robustness of our results with sensi-
tivity analyses that omitted one study at a time. Potential
publication bias was assessed using the Egger test and is
presented graphically via Begg funnel plots [15, 16],
which were adjusted using rank correlation tests.
Results
Search results
Figure 1 summarizes the review process. Of the 1599 ar-
ticles retrieved during the initial search, 1086 articles
were excluded at the title and abstract level because they
were not relevant, 232 articles were reviews, and 239 ar-
ticles were animal studies. Among the articles retrieved
in complete form, three articles described on-going stud-
ies, 19 articles were excluded due to unrelated outcomes,
two articles utilized other cells as the control, seven arti-
cles described studies with no randomization, and four
articles described studies with no control group or a
control arm that also received stem cells. Thus, seven
trials with a total of 482 patients and a follow-up period
≥12 months were eligible for inclusion [5–11].
Study characteristics
Table 1 describes the methodological quality of the in-
cluded RCTs. Table 2 summarizes the main features of
the included studies. The included trials were published
between 2010 and 2015. The pooled analysis included
227 control patients and 254 patients who received stem
cell therapy. The sample sizes for stem cell therapy
ranged from 23 to 160, with the longest follow-up ran-
ging from 12 to 60 months. Of the seven identified trials,
five trials were multicentre studies [5, 6, 9–11]. Table 3
presents patient and procedural characteristics for the
included RCTs. Within each study the control and treat-
ment groups were similar with respect to mean age and
gender (p > 0.05). The mean patient age in these trials
ranged from 45 to 60 years. The injection routes were
intracoronary for all trials except for that performed by
Henry et al. [10], who used an intramyocardial route.
BMMNCs or CD34+ cells were the major cell types in-
volved in these trials. Considerable heterogeneity in the
number of cells used for cell therapy was observed
(range = 0.35 × 108 to 2.95 × 108 cells).
Co-primary outcomes
Meta-analytic pooling for mortality rate revealed that,
compared with control treatment, bone marrow-derived
stem cell therapy was associated with a significant
Fig. 1 Review process. This scheme diagrams the reviewing process. RCT randomised control trial
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decrease in mortality rate (19.7% (42/213) in the cell
group vs. 27.1% (54/199) in the control group; 95% CI –
0.16 to –0.00, I2 = 52%, p = 0.04) (Fig. 2).
With respect to changes in LVEF, only a trend of im-
provement in LVEF was observed in the cell group at
short-term follow-up (1.83% increase; 95% CI –0.27 to
3.94, I2 = 74%, p = 0.09; Fig. 3a). However, compared with
control treatment, bone marrow-derived stem cell
therapy achieved significant improvement in LVEF at
mid-term follow-up (3.53% increase; 95% CI 0.76 to
6.29, I2 = 88%, p = 0.01) (Fig. 3b). Bone marrow-derived
stem cell therapy reduced LVESV (–24.94 ml; 95% CI –
41.37 to –8.51, I2 = 0%, p = 0.003) after mid-term
follow-up but did not influence left ventricular end-
diastolic chamber size at any of the follow-up time
points (–2.69 mm; 95% CI –7.71 to 2.34, I2 = 80%, p =
0.29 at the short-term follow-up;–0.71 mm; 95% CI –
1.87 to 0.46, I2 = 17%, p = 0.24 at the mid-term follow-
up) (Fig. 3c).
Secondary outcomes
No significant improvement in 6MWT results was
identified in the cell group compared with the control
group at either follow-up duration (39.89 m increase;
95% CI –50.22 to 129.99, I2 = 88%, p = 0.39 at the
short-term follow-up; 51.56 m increase; 95% CI –
24.09 to 127.20, I2 = 95%, p = 0.18 at the mid-term
follow-up) (Fig. 4).
Sensitivity analysis and publication bias
A sensitivity analysis that excluded each individual study
confirmed the significance of the mortality results ob-
tained from the overall analysis. Additionally, no publi-
cation bias was found.
Discussion
Based on currently available data, the main results of the
meta-analysis are as follows: 1) Bone marrow-derived stem
cell therapy may have reduced mortality rate and provided
mild-to-moderate benefits in cardiac systolic function at
mid-term follow-up for patients with NIDCM; 2) this ther-
apy produced no observed improvement in exercise
capacity.
NIDCM, an end-stage cardiomyopathy without coron-
ary artery disease, often progresses into symptomatic HF
due to a lack of effective pharmaceutics and interven-
tional strategies. Patients with NIDCM exhibit a 31%
mortality rate [17]. Thus, reducing this mortality rate is
critical. At present, the major treatments for NIDCM
are medication and heart transplantation. However, due
to the limited curative effects and poor prognoses asso-
ciated with these approaches, stem cell therapy has be-
come a focus of clinical research [18].











Bocchi EA et al. 2010 [11] L L H H L
Vrtovec B et al. 2011 [6] L H H L L
Vrtovec B et al. 2013 [5] L H H L L
Martino H et al. 2015 [9] L L L L L
Henry TD et al. 2014 [10] L L L L L
Sant’Anna RT et al. 2014 [8] L L H L L
Seth S et al. 2010 [7] L H H H L
L low risk, H high risk (Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0)
Table 2 Main feature of included studies
Source Sample size, n Follow-up duration, months Setting Study design Primary endpoint
Bocchi EA et al. 2010 [11] 23 22 Multicentre RCT LVEF
Vrtovec B et al. 2011 [6] 45 12 Multicentre RCT LVEF, exercise capacity
Vrtovec B et al. 2013 [5] 110 60 Multicentre RCT LVEF, LVEDD
Martino H et al. 2015 [9] 160 12 Multicentre RCT LVEF
Henry TD et al. 2014 [10] 29 12 Multicentre RCT Safety
Sant’Anna RT et al. 2014 [8] 30 12 Single centre RCT LVEF
Seth S et al. 2010 [7] 85 36 Single centre RCT LVEF, mortality
LVEDD left ventricular end-diastolic dimension, LVEF left ventricular ejection fraction, RCT randomised control trial
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In this systematic review, a promising result was obtained;
mortality rate decreased more in the stem cell group than in
the control group during 12 to 60 months of follow-up.
With respect to left ventricular systolic function, stem cell
therapy did not significantly improve LVEF until after mid-
term (6–12 months) follow-up (a 3.53% increase in LVEF).
Consistently, reduced end-systolic left ventricular chamber
size was not observed until after 6 months of follow-up. We
hypothesize that the “delayed” nature of LVEF enhancement
might be due to cardiac remodelling mechanisms. Paracrine
stem cell mechanisms, rather than mechanisms of the
transplanted cells themselves, play important roles in LVEF
improvement [19, 20]. Anti-inflammatory, immunomodula-
tory, and antioxidant activities play critical roles in reversing
cardiac remodelling. Recent studies [21, 22] have demon-
strated that stem cell transplantation can prevent remodel-
ling and stimulate reverse left ventricular remodelling, a
process that requires an average of 3 to 12 months. Research
has suggested that, in addition to paracrine effects, other ef-
fects, such as the mircrine phenomenon, contribute to the
therapeutic effects of stem cells. In this phenomenon, miR-
499-overexpressing human cardiac stem cells are regarded
as “donors”, and nearby cardiac stem cells serve as “recipi-
ents”. Observations of connexin 43 have suggested the po-
tential translocation of miR-499 via gap junction channels.
This new mode of cell-to-cell communication is known as
mircrine communication, which also requires time to affect
cells [23]. Interestingly, the results from cell therapy for
ICM suggest a similar magnitude of LVEF improvement but
more rapid LVEF recovery [16, 24, 25]. Differences in the
onset time of cell therapy may be attributed to mechanisms
that contribute to the progression of NIDCM and ICM. By
definition, the most conspicuous difference between ICM
and NIDCM is the existence of atherosclerotic lesions in the
epicardial coronary arteries in patients with ICM and the ab-
sence of such lesions in patients with NIDCM. In theory,
these lesions produce sufficient homing signals to induce
stem cell engraftment in the damaged myocardium. Another
abnormality in ICM is the presence of typically extensive
dysfunctional areas of myocardial scarring; such regions are
less pronounced or absent in patients with NIDCM [26, 27].
From our meta-analysis, we could not identify a bene-
ficial effect of bone marrow-derived stem cell therapy on
6MWT results during follow-up. This finding might be
attributable to the limited improvement in left ventricu-
lar systolic function (3.53%) observed in the cell group.
This effect was statistically significant but clinically in-
sufficient to produce a noticeable change in exercise
capacity. Recent studies [28, 29] have reported that
6MWT distance is positively correlated with the
Table 3 Patients and procedural characteristics
Source Mean age, years Cell type Cell transplanted, n Route of injection Baseline LVEF, %
Bocchi EA et al. 2010 [11] 51 ± 15 BM-CD34+ 0.96 × 108 IC 21.8 ± 3.8
Vrtovec B et al. 2011 [6] 52 ± 8 BM-CD34+ 1.23 ± 0.23 × 108 IC 25.9 ± 4.6
Vrtovec B et al. 2013 [5] 53 ± 8 BM-CD34+ 1.13 ± 0.26 × 108 IC 24.0 ± 4.0
Martino H et al. 2015 [9] 51 ± 11 BM-MNCs 2.36 (1.76–2.95) × 108 IC 24.0 ± 9.6
Henry TD et al. 2014 [10] 60 ± 16 BM-MNCs 1.65 (0.35–2.95) × 108 IM 25.8 ± 7.0
Sant’Anna RT et al. 2014 [8] 48 ± 9 BM-MNCs 1.06 × 108 IC 25.1 ± 4.0
Seth S et al. 2010 [7] 45 ± 15 BM-MNCs 1.68 ± 0.96 × 108 IC 22.5 ± 8.3
BM bone marrow, IC intracoronary, IM intramyocardial, LVEF left ventricular ejection fraction, MNC mononuclear cell
Fig. 2 Mortality of stem cell therapy. Forest plot of the weighted mean differences revealed a reduced mortality rate after cell therapy compared
with the control treatment. CI confidence interval
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Fig. 3 The effect of stem cell therapy on left ventricular structure and function. a Forest plot of the effect of stem cell therapy on left ventricular
ejection fraction. b, c Forest plots of the effect of stem cell therapy on left ventricular end-systolic volume (b) and left ventricular end-diastolic
chamber size (c). CI confidence interval, IV inverse variance, SD standard deviation
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magnitude of increase in cardiac output (r = 0.63), and
inadequate output increase may therefore account for a
lack of change in 6MWT results after stem cell therapy.
Certain research has revealed that the potential of
autologous bone marrow-derived stem cell therapy for
cardiac repair may be limited by patient-related factors,
such as age and gender. Stem cell therapy in patients
with acute myocardial infarction has been particularly
effective at improving LVEF for ageing patients. This
phenomenon likely occurs because ageing patients are
likely to suffer from impaired endothelium and to ex-
hibit inadequate physiological angiogenesis responses to
ischaemia; thus, such patients will tend to greatly benefit
from supplementation with stem cells [30]. Gender may
be a significant determinant of stem cell function via the
direct actions of sex steroids on these cells. A prior
study found greater post-ischaemic myocardial func-
tional recovery after an intracoronary infusion of female
stem cells than after an intracoronary infusion of male
stem cells [31].
Limitations
Significant heterogeneity was noted among the trials
with respect to left ventricular function and quality of
life. This heterogeneity was due to multiple factors, in-
cluding the number of patients enrolled, whether trials
were single-centre or multicentre studies, the number of
cells injected, routes of injection, and the use of granulo-
cyte colony-stimulating factor (G-CSF) therapy in three
trials [5, 6, 9]. The cell types used in the included trials are
limited to BM-CD34 cells and BMMNCs. Nonetheless, be-
cause three original papers involving 178 patients used
BM-CD34 cells as the cell source and four trials involving
304 patients used BMMNCs, additional analyses would
have been unreliable. Second, in this study, cardiac function
referred only to systolic function. When more data are
available, it would be interesting to explore the efficacy of
stem cells for improving diastolic function.
Conclusions
Bone marrow-derived stem cell therapy may have produced
a net beneficial effect with respect to reducing mortality in
patients with NIDCM. When such therapy was utilised, a
mild-to-moderate LVEF increase was only observed during
mid-term follow-up, with no improvement in exercise cap-
acity. Future research should focus on the most effective cell
type and dosage for stem cell therapy.
Abbreviations
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